NFGH
ATYR

Nan Fung Group Holdings’s aTyr Pharma ATYR Stock Holding History

Nan Fung Group Holdings’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-23,500
Closed -$176K – 58
2021
Q4 		$176K Buy
+23,500
New +$196K 0.05% 50

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Nan Fung Group Holdings's ATYR Position: Q1 2022 in Review

Nan Fung Group Holdings sold out of aTyr Pharma (ATYR) in Q1 2022, closing a stake of 23,500 shares — an estimated $176K sold.

Nan Fung Group Holdings first reported a position in ATYR in Q4 2021 and held it in 1 quarter. The position peaked at $176K in Q4 2021. 41 funds tracked by Wall St. Rank hold ATYR as of Q1 2022.

  • Nan Fung Group Holdings reported no remaining aTyr Pharma position as of Q1 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 23,500 aTyr Pharma shares in Q1 2022, an estimated $176K.
  • Nan Fung Group Holdings first reported a position in aTyr Pharma in Q4 2021 and held it in 1 quarter.
  • Nan Fung Group Holdings's aTyr Pharma position peaked at $176K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2022.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.